CILENGITIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME AND UNMETHYLATED MGMT GENE PROMOTER: SAFETY RUN-IN RESULTS FROM A RANDOMIZED, CONTROLLED, PHASE II STUDY (CORE)

被引：0
|
作者：
Mikkelsen, T. [1 ]
Nabors, L. B. [2 ]
Fink, K. [3 ]
Chan, M. [4 ]
Trusheim, J. [5 ]
Raval, S. [6 ,10 ]
Hicking, C. [7 ]
Henslee-Downey, J. [9 ]
Picard, M. [7 ]
Reardon, D. [8 ]
机构：
[1] Henry Ford Hlth Syst, Detroit, MI USA
[2] Univ Alabama, Neurooncol Program, Birmingham, AL USA
[3] Baylor Univ, Med Ctr, Dallas, TX USA
[4] Wake Forest Univ Hlth Sci, Winston Salem, NC USA
[5] Virginia Piper Canc Inst, Minneapolis, MN USA
[6] Monmouth Med Ctr, Long Branch, NJ USA
[7] Merck KGaA, Darmstadt, Germany
[8] Duke Univ, Med Ctr, Preston Robert Tisch Brain Tumour Ctr, Durham, NC USA
[9] EMD Serono Inc, Rockland, MA USA
[10] Garden State Neurol & Neurooncol, Long Branch, NJ USA
来源：
ANNALS OF ONCOLOGY | 2010年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：173 / 173
页数：1
相关论文
共 50 条
  • [41] Phase II trial of erlotinib with temozolomide and concurrent radiation therapy in patients with newly diagnosed glioblastoma multiforme: Final results
    Peereboom, D. M.
    Brewer, C. J.
    Sub, J. H.
    Stevens, G. H.
    Barnett, G. H.
    Toms, S. A.
    Elson, P.
    Vogelbaum, M. A.
    Weil, R. J.
    NEURO-ONCOLOGY, 2006, 8 (04) : 448 - 448
  • [42] IMPACT OF 18F-DOPA PET ON RADIOTHERAPY TARGET VOLUMES FOR NEWLY DIAGNOSED MGMT UNMETHYLATED GLIOBLASTOMA PATIENTS; PRELIMINARY RESULTS OF A PHASE II DOSE-ESCALATION TRIAL
    Brinkmann, Debra
    Pafundi, Deanna
    Hunt, Christopher
    Lowe, Val
    Yan, Elizabeth
    Brown, Paul D.
    Zakhary, Mark
    Zhang, Yan
    Seaberg, Maasa
    Tseung, Hok Seum Wan Chan
    Sarkaria, Jann
    Laack, Nadia
    NEURO-ONCOLOGY, 2018, 20 : 225 - 225
  • [43] ANLOTINIB COMBINED WITH STUPP REGIMEN IN TREATING PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME: A PHASE II PILOT STUDY
    Lai, Shuzhen
    Chen, Yuanyuan
    NEURO-ONCOLOGY, 2020, 22 : 52 - 52
  • [44] A phase 0/1b study of AZD1390 plus radiotherapy in newly-diagnosed, MGMT-unmethylated glioblastoma patients
    Sanai, Nader
    Desai, Siddhi
    Margaryan, Tigran
    Molloy, Jennifer
    LoCascio, Costanza
    Elliott, Mackenna
    Harmon, Jocelyn
    Hong, Amy
    Melendez, Ernesto Luna
    Wanebo, John
    Braun, Kelly
    Kennedy, William
    Garcia, Michael
    Yoo, Wonsuk
    Tovmasyan, Artak
    Tien, An-Chi
    Mehta, Shwetal
    CANCER RESEARCH, 2024, 84 (07)
  • [45] A PHASE 0/1B STUDY OF AZD1390 PLUS RADIOTHERAPY IN NEWLY DIAGNOSED, MGMT-UNMETHYLATED AND RECURRENT GLIOBLASTOMA PATIENTS
    Sanai, Nader
    Umemura, Yoshie
    Desai, Siddhi
    Margaryan, Tigran
    Molloy, Jennifer
    Locascio, Costanza
    Elliott, Mackenna
    Harmon, Jocelyn
    Hong, Amy
    Melendez, Ernesto Luna
    Wanebo, John
    Braun, Kelly
    Kennedy, William R.
    Garcia, Michael
    Yoo, Wonsuk
    Tovmasyan, Artak
    Tien, An-Chi
    Mehta, Shwetal
    NEURO-ONCOLOGY, 2024, 26
  • [46] Randomized phase II/III trial of veliparib or placebo in combination with adjuvant temozolomide in newly diagnosed glioblastoma (GBM) patients with MGMT promoter hypermethylation (Alliance A071102).
    Sarkaria, Jann Nagina
    Ballman, Karla V.
    Kizilbash, Sani Haider
    Sulman, Erik P.
    Giannini, Caterina
    Mashru, Sandeep H.
    Piccioni, David Eric
    Friday, Bret Edward Buckley
    Dixon, Jesse G.
    Kabat, Brian
    Laack, Nadia N.
    Hu, Leland
    Kumthekar, Priya
    Ellingson, Benjamin M.
    Anderson, S. Keith
    Galanis, Evanthia
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [47] SAFETY LEAD-IN RESULTS FOR QBS10072S IN THE INDIVIDUAL SCREENING TRIAL OF INNOVATIVE GLIOBLASTOMA THERAPY (INSIGHT) TRIAL, A RANDOMIZED ADAPTIVE PLATFORM TRIAL FOR NEWLY DIAGNOSED MGMT UNMETHYLATED GLIOBLASTOMA
    Rahman, Rifaquat
    Trippa, Lorenzo
    Aquilanti, Elisa
    Lee, Eudocia
    Arrillaga-Romany, Isabel
    Wiley, Jennifer
    Chukwueke, Ugonma
    McFaline-Figueroa, Jose
    Partridge, Kathryn
    Beroukhim, Rameen
    Nayak, Lakshmi
    Batchelor, Tracy
    Lu-Emerson, Christine
    Drappatz, Jan
    Lassman, Andy
    Welch, Mary
    Ahluwalia, Manmeet
    Bi, Wenya
    Arnaout, Omar
    Haas-Kogan, Daphne
    Tanguturi, Shyam
    Aizer, Ayal
    Doherty, Lisa
    Fell, Geoffrey
    Lavallee, Maria
    Smokovich, Anna
    Peabody, Shannon
    Westergaard, Catharina
    Bhutani, Vasvi
    Russ, Alyssa
    Barlow, Brooke
    Chiocca, Ennio
    Ringold, Gordon
    Weitzman, Ron
    Holland, Jaymes
    Reardon, David
    Ligon, Keith
    Wen, Patrick
    NEURO-ONCOLOGY, 2024, 26
  • [48] A randomized, double-blind, controlled phase IIb study of the safety and efficacy of ICT-107 in newly diagnosed patients with glioblastoma multiforme following resection and chemoradiation.
    Hawkins, Elma S.
    Aiken, Robert
    Chandler, James
    Fink, Karen L.
    Glantz, Michael J.
    Grewal, Jai
    Gruber, Michael L.
    Kesari, Santosh
    Landolfi, Joseph C.
    LaRocca, Renato V.
    Lesser, Glenn Jay
    Markert, James
    Mayer, Tina M.
    O'Rourke, Donald
    Peereboom, David M.
    Phuphanich, Surasak
    Schiff, David
    Sloan, Andrew E.
    Stea, Baldassarre
    Zhu, Jay-Jiguang
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [49] Weak MGMT gene promoter methylation confers a clinically significant survival benefit in patients with newly diagnosed glioblastoma: a retrospective cohort study
    Pinson, H.
    Hallaert, G.
    Van der Meulen, J.
    Dedeurwaerdere, F.
    Vanhauwaert, D.
    Van den Broecke, C.
    Van Dorpe, J.
    Van Roost, D.
    Kalala, J. P.
    Boterberg, T.
    JOURNAL OF NEURO-ONCOLOGY, 2020, 146 (01) : 55 - 62
  • [50] Weak MGMT gene promoter methylation confers a clinically significant survival benefit in patients with newly diagnosed glioblastoma: a retrospective cohort study
    H. Pinson
    G. Hallaert
    J. Van der Meulen
    F. Dedeurwaerdere
    D. Vanhauwaert
    C. Van den Broecke
    J. Van Dorpe
    D. Van Roost
    J. P. Kalala
    T. Boterberg
    Journal of Neuro-Oncology, 2020, 146 : 55 - 62
12345